Akebia (AKBA) Therapeutics announced that it has commenced an underwritten public offering. All shares are being offered by Akebia. Leerink Partners and Piper Sandler & Co. are acting as joint bookrunning managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKBA:
- Akebia Therapeutics’ Strong Market Performance and Strategic Initiatives Drive Buy Rating
- Akebia price target raised to $6 from $4 at Piper Sandler
- Akebia Therapeutics Faces Global Regulatory Challenges Amid Brexit and EU Changes
- Akebia Therapeutics Reports Progress in Vafseo Launch
- Akebia Therapeutics’ Earnings Call Highlights Vafseo Success